Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, granting the company the right, but not the obligation, to sell up to $50 million in newly issued common stock. The facility allows sales via market open, intraday, pre-market, post-market, and block purchases at a 6% discount to VWAP, subject to a minimum price of $0.10 per share. Issuances are capped at 3,072,118 shares (19.99% of outstanding stock) unless shareholder approval is obtained or the average purchase price exceeds $0.3663. Net proceeds will fund product development and working capital. Traws Pharma operates in the biopharmaceutical industry.
